Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Neuren Pharmaceuticals (NEU AU)
Watchlist
74
Analysis
Health Care
•
Australia
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company. The Company researches neurological and metabolic disorders.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Brilliance China Automotive
•
20 Aug 2023 07:19
Index Rebalance & ETF Flow Recap: ASX, NEXT50, MVMVA, MVMVW, Celltrion, Brilliance, KQ150, HSCI
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
681 Views
Share
bullish
•
Ramelius Resources
•
17 Aug 2023 06:04
S&P/ASX Index Rebalance Preview: Potential Adds Have Outperformed
We forecast 26 changes across the ASX50, ASX100, ASX 200 and ASX300 indices at the September rebalance. There is big flow and impact on a lot of...
Brian Freitas
Follow
930 Views
Share
bullish
•
Neuren Pharmaceuticals
•
10 Aug 2023 19:31
Quiddity Leaderboard ASX Sep 23: Potential Surprises and Final Thoughts
I expect ASX 200 and 300 Expected ADDs to outperform the ASX 200 and 300 Expected DELs over the next few weeks since there are many names on both...
Janaghan Jeyakumar, CFA
Follow
785 Views
Share
bullish
•
Wistron Corp
•
23 Jul 2023 08:41
Index Rebalance & ETF Flow Recap: ASX, SK Telecom, Yuanta ETFs
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
703 Views
Share
bullish
•
Data#3 Ltd
•
19 Jul 2023 05:09
S&P/ASX200 Ad Hoc Index Rebalance & Update to Potential Changes in September
Ventia replaces Blackmores in the ASX200 at the close on 21 July. That also leads to changes to potential adds/deletes in September. WBT and DTL...
Brian Freitas
Follow
807 Views
Share
First
Previous
7
8
9
10
11
12
13
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.5
x